General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients...

Asthma deaths levels increase by a quarter in a decade

Asthma deaths levels increase by a quarter in a decade

July 26 2018 There were 1,320 deaths due to asthma in England and Wales in 2017, the highest...

NPA and Age UK ask for help on building polypharmacy dossier

NPA and Age UK ask for help on building polypharmacy dossier

July 25 2018 The National Pharmacy Association is asking its members for case studies on...

Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

July 24 2018 New Health Secretary Matt Hancock has called for investment in primary care and...

NHS Digital seeks views on SCR with Additional Information

NHS Digital seeks views on SCR with Additional Information

July 24 2018 A survey to assess the benefits and/or disadvantages of health professionals...

  • General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

    General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

    Tuesday, 31 July 2018 15:31
  • Asthma deaths levels increase by a quarter in a decade

    Asthma deaths levels increase by a quarter in a decade

    Thursday, 26 July 2018 15:08
  • NPA and Age UK ask for help on building polypharmacy dossier

    NPA and Age UK ask for help on building polypharmacy dossier

    Wednesday, 25 July 2018 13:46
  • Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

    Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

    Tuesday, 24 July 2018 12:53
  • NHS Digital seeks views on SCR with Additional Information

    NHS Digital seeks views on SCR with Additional Information

    Tuesday, 24 July 2018 12:41

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

legal high spiceJuly 13 2015

Health professionals are being asked to be alert to the possibility of toxicity arising from cannabis substitutes after an increase in the number of hospitalisations.

‘Spice’ or synthetic cannabinoids can mimic the effect of cannabis, and can be sprayed onto herbal matter or sold as powder to be added to cigarettes. The most harmful chemicals may be in brands like Vertex, Sweet Leaf Obliteration and Skyhigh but other brands also contain them, says Public Health England.

“Brand names and what they contain are likely to change over time,” it warns. “The chemicals currently causing the most concern are AB-CHMINICA, and MMBCHMINACA (also known as MDMB-CHMICA). These are currently not controlled drugs.”

Acute toxicity may present as dizziness, persistent nausea or vomiting, chest pains, dyspnoea, fast or irregular heartbeat and convulsions. “These effects should be managed symptomatically and may need urgent referral to A&E. Less severe or less acute physical or psychological problems should be assessed and managed symptomatically as for any other users of psychoactive drugs.”

PHE’s advice has been sent out to health professionals in England, and has also been forwarded by the Scottish Government. The warning follows cases where users where admitted to hospital in North Wales, Lancashire and Cheshire, and reports of deaths in Germany and Sweden.

Links:

PHE letter    

Scottish Government letter   

Practice News

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...